Protein-Antibody Conjugates (PACs): A Major Breakthrough in Cancer Research
Recently, a team of scientists from the University of Massachusetts (U.S.) engineered a nanoparticle that has the potential to revolutionize treatment of ailments like cancer and many other incurable diseases.
- This new research combines two different approaches to drug delivery - biologics and antibody-drug conjugates (ADCs) - to produce nanoparticles called protein-antibody conjugates (PACs) that can be used for precise and effective targeted drug delivery to the specific affected cells.
Biologics
- Biologics are products isolated from various natural sources - human, animal, or microorganisms and represent a promising approach to drug delivery.
- Biologics can be composed of proteins, sugars, or nucleic acids ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 India’s Evolving Crime Landscape: NCRB Report 2024
- 2 Artificial Intelligence and Energy Efficiency: Powering the Green Transition
- 3 India-Nordic Summit 2026: Key Outcomes and Strategic Significance
- 4 Water Governance in India: Addressing the Crisis of Scarcity and Management
- 5 Nuclear Energy in India: Roadmap for Achieving 100 GW Capacity by 2047
- 6 India’s Fertilizer Subsidy Burden and Sustainability Concerns
- 7 Conduct of Competitive Exams in India: Issues, Challenges, and Reforms
- 8 Indian Rupee Depreciation in a Volatile Global Economy
- 9 India and the QUAD: Opportunities, Challenges, and the Road Ahead
- 10 AI-Powered Financial Inclusion in India

